Repurposing of Omarigliptin as a Neuroprotective Agent Based on Docking with A(2A) Adenosine and AChE Receptors, Brain GLP-1 Response and Its Brain/Plasma Concentration Ratio after 28 Days Multiple Doses in Rats Using LC-MS/MS

The authors in the current work suggested the potential repurposing of omarigliptin (OMR) for neurodegenerative diseases based on three new findings that support the preliminary finding of crossing BBB after a single dose study in the literature. The first finding is the positive results of the dock...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayoub, Bassam M., Michel, Haidy E., Mowaka, Shereen, Hendy, Moataz S., Tadros, Mariam M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915074/
https://www.ncbi.nlm.nih.gov/pubmed/33567615
http://dx.doi.org/10.3390/molecules26040889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915074/
https://www.ncbi.nlm.nih.gov/pubmed/33567615
http://dx.doi.org/10.3390/molecules26040889

Ejemplares similares